I haven’t had a chance to review the data yet, but Danny Parker forwarded me these links moments ago:
This just off the medical press and called out by Dr. Robert Orlowski.
Oral protease inhibitor, Nelfinavir, used against HIV, enhances the activity of Bortezomib against myeloma. Even more important, it appears to overcome resistance in myeloma cells to Bortezomib or Carfilzomib.
Clinical trials under way:
Thanks, Danny! See what you think everybody and please chime-in. Game changer or just another myeloma therapy “blip?”
Feel good and keep smiling! Pat